Worth reading
34Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Avoiding a definitive answer
How definitive the wording is.Agreements reached under this partnership
Business alliance2385Soiken Holdings Inc.
Alliance partnerカーブジェン株式会社
Details of the alliance
- 1
『うつ病のバイオマーカー：SITH-1抗体』の診断を自動化するAIシステムの開発
- 2
カーブジェンが独自開発した画像AI解析技術の応用
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
About the partner
Business Description独自開発した画像AI解析技術を有し、厚生労働省よりプログラム医療機器（SaMD）の承認取得の実績を有する
LocationShibuya, Tokyo
Impact on Business Performance
当期（2025年6月期）の業績への影響は軽微であると見込んでおります。
Alliance start date2025年5月7日より前に開始済み（具体的な開始日はNot disclosed）
| Item | Details |
|---|---|
| Name of alliance partner | カーブジェン株式会社 |
| Alliance partner's business activities | 独自開発した画像AI解析技術を有し、厚生労働省よりプログラム医療機器（SaMD）の承認取得の実績を有する |
| Alliance partner's location | Shibuya, Tokyo |
| Type of alliance | Business alliance |
| Details of the alliance | 『うつ病のバイオマーカー：SITH-1抗体』の診断を自動化するAIシステムの開発, カーブジェンが独自開発した画像AI解析技術の応用 |
| Alliance start date | 2025年5月7日より前に開始済み（具体的な開始日はNot disclosed） |
| Impact on Business Performance | 当期（2025年6月期）の業績への影響は軽微であると見込んでおります。 |
Items this document does not state (16)
Alliance partner's capitalAlliance partner's net salesAlliance partner's operating incomeNumber of shares acquiredAcquisition priceShareholding ratioOverview of the joint ventureOwnership ratioDispatch of directors and officersContract PeriodNumerical targets under the allianceShareholding PolicyDate of board resolutionContract DateShare Acquisition Date and Payment DateChange in major shareholders
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.総医研グループのバイオマーカー技術と、カーブジェンの画像AI解析技術を活用し、うつ病の診断をより迅速かつ正確にするため。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.